AAP
RNTX

Ardsley Advisory Partners’s Rein Therapeutics RNTX Stock Holding History

Ardsley Advisory Partners’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,500
Closed -$83K – 162
2018
Q3 		$83K Buy
+1,500
New +$101K 0.01% 147

Other funds holding RNTX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PL
Parkwood LLC Cleveland, Ohio $1.13B AUM 32.89% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return
JA
JOYN Advisors Atlanta, Georgia $300M AUM 14.91% 1-Year Est. Return

Ardsley Advisory Partners's RNTX Position: Q4 2018 in Review

Ardsley Advisory Partners sold out of Rein Therapeutics (RNTX) in Q4 2018, closing a stake of 1,500 shares — an estimated $83K sold.

Ardsley Advisory Partners first reported a position in RNTX in Q3 2018 and held it in 1 quarter. The position peaked at $83K in Q3 2018. 23 funds tracked by Wall St. Rank hold RNTX as of Q4 2018.

  • Ardsley Advisory Partners reported no remaining Rein Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Ardsley Advisory Partners sold 1,500 Rein Therapeutics shares in Q4 2018, an estimated $83K.
  • Ardsley Advisory Partners first reported a position in Rein Therapeutics in Q3 2018 and held it in 1 quarter.
  • Ardsley Advisory Partners's Rein Therapeutics position peaked at $83K in Q3 2018.
  • 23 funds tracked by Wall St. Rank held Rein Therapeutics as of Q4 2018.

Based on Ardsley Advisory Partners's 13F filing for Q4 2018, filed 14 Feb 2019.